FDA: Competition slowing for first-in-class drugs

First-in-class drugs are facing less competition today than they did in the past, according to a new analysis conducted by FDA.

FDA Commissioner Scott Gottlieb described the analysis to a congressional committee Wednesday, and said FDA plans to issue guidance on seamless clinical trials that could speed the entry of competing drugs with the same mechanism of action as first-in-class therapies...